EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

FDA DecisionNegative

AI Analysis

Summary

Exelixis' cancer drug review was delayed by the FDA by three months, causing the stock to decline. William Blair anticipates continued volatility in the near term.

Outcome Details

FDA review extended by three months

Importance:7/10

Sentiment:

-0.70

FDAPDUFA delayoncologyreview extension

Related Companies

$EXEL

Read the original article

Published by yahoo_finance on September 11, 2026 8:19 PM

Read Original